Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in late preclinical evaluation stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden.
Frequently asked questions
What sector does Elicera Therapeutics AB (ELIC) operate in?
Elicera Therapeutics AB belongs to the Healthcare sector and operates in the Biotechnology industry.
What is Elicera Therapeutics AB (ELIC) current stock price?
As of the latest data, Elicera Therapeutics AB stock price is SEK 2.95, with a previous close of SEK 2.97. Elicera Therapeutics AB lost -SEK 0.02 in the last trading session, representing a -0.67% loss.
What is Elicera Therapeutics AB (ELIC) current market capitalization?
Elicera Therapeutics AB market cap is approximately 196.54 million.
What is Elicera Therapeutics AB (ELIC) Earnings Per Share (EPS)?
The trailing EPS is -SEK 0.25, and the forward EPS is -SEK 0.46.
What is Elicera Therapeutics AB (ELIC) EBITDA?
Elicera Therapeutics AB EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -5.12 million.
Does Elicera Therapeutics AB (ELIC) pay dividends?
No. Elicera Therapeutics AB does not pay a dividend.
What is Elicera Therapeutics AB (ELIC) beta (volatility) score?
Elicera Therapeutics AB has a beta of 0.288, indicating lower volatility than the overall market.
